Non-small cell lung cancer (NSCLC) Gene Panel

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and is a heterogeneous disease with a range of genomic variants that promote tumour growth. Several biomarkers have emerged as predictive gene alterations that have been identified to impact therapy selection while prognostic markers are indicative of patient survival independent of the treatment.

Predictive molecular biomarkers include EGFR mutations, KRAS mutations, BRAF mutations, METex14 skipping mutations, ALK gene rearrangements, RET gene rearrangements, ROS1 gene rearrangements and NTRK1/2/3 gene fusions. Testing for these alterations is important for identification of potentially efficacious targeted therapies that can be accessed under the Pharmaceutical Benefit Scheme, as well as avoidance of therapies unlikely to provide clinical benefit. The KRAS oncogene is a prognostic biomarker, and its presence indicates poor survival for patients with NSCLC when compared to the patients with absence of KRAS mutations, independent of therapy.

The lung panel offers broad molecular profiling for NSCLC and identifies all of the classic actionable biomarkers described in the clinical algorithm using a single assay.